Disc Medicine, Inc. (IRON)
NASDAQ:IRON
Want to see IRON full AI Analyst Report?
IRON Stock Chart & Stats
$71.77
$0.74(1.19%)
At close: 4:00 PM EST
$71.77
$0.74(1.19%)
Day’s Range― - ―
52-Week Range$40.00 - $99.50
Previous CloseN/A
Volume41.94K
Average Volume (3M)451.68K
Market Cap
$2.60B
Enterprise Value$2.60B
Total Cash (Recent Filing)$730.16M
Total Debt (Recent Filing)$31.06M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 06, 2026EPS Estimate
-1.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.64
Shares Outstanding38,199,090
10 Day Avg. Volume437,404
30 Day Avg. Volume451,683
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.77K
Enterprise Value/Ebitda-10.64
Forecast
1Y Price Target
$103.14Price Target Upside43.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-6.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet LiquiditySizable equity and very low leverage provide durable funding capacity to support multi-year clinical programs. This reduces immediate refinancing pressure, allowing management to prioritize trial completion and regulatory interactions without urgent capital raises that could overly dilute shareholders.
Pivotal Trial Enrollment CompletedCompleting and expanding APOLLO enrollment materially lowers execution risk tied to patient recruitment and preserves the planned timeline for topline data. This operational progress strengthens the company's ability to generate the definitive evidence required for regulatory review and potential label-setting outcomes.
Cash Runway Into 2029 (per Filings)A multi-year cash runway supports near- and mid-term development programs and potential resubmission activities without immediate dependence on dilutive financing. That liquidity enables the company to complete APOLLO and other trials, preserving strategic optionality around partnerships or commercialization planning.
Bears Say
Pre-revenue With Widening LossesBeing pre-revenue while losses and cash burn have materially increased creates persistent financing and dilution risk. Continued negative free cash flow means management must balance investment in clinical programs with the need to preserve capital, potentially forcing trade-offs or future equity raises.
Regulatory Setback Raises Evidentiary BarThe CRL shifts approval reliance onto pivotal APOLLO outcomes and raises the standard of evidence linking biomarker changes to meaningful clinical benefit. This increases regulatory execution risk and extends the timeline to potential U.S. approval, affecting commercialization and revenue timing.
Restructuring And Workforce ReductionA ~20% headcount reduction focused on commercial readiness signals diminished near-term go-to-market capacity and introduces execution risk. While it cuts costs, it may delay commercial planning and limit the company's ability to scale rapidly if regulatory outcomes improve, adding strategic uncertainty.
Disc Medicine News
IRON FAQ
What was Disc Medicine, Inc.’s price range in the past 12 months?
Disc Medicine, Inc. lowest stock price was $40.00 and its highest was $99.50 in the past 12 months.
What is Disc Medicine, Inc.’s market cap?
Disc Medicine, Inc.’s market cap is $2.60B.
When is Disc Medicine, Inc.’s upcoming earnings report date?
Disc Medicine, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Disc Medicine, Inc.’s earnings last quarter?
Disc Medicine, Inc. released its earnings results on May 05, 2026. The company reported -$1.65 earnings per share for the quarter, missing the consensus estimate of -$1.623 by -$0.027.
Is Disc Medicine, Inc. overvalued?
According to Wall Street analysts Disc Medicine, Inc.’s price is currently Undervalued.
Does Disc Medicine, Inc. pay dividends?
Disc Medicine, Inc. does not currently pay dividends.
What is Disc Medicine, Inc.’s EPS estimate?
Disc Medicine, Inc.’s EPS estimate is -1.71.
How many shares outstanding does Disc Medicine, Inc. have?
Disc Medicine, Inc. has 38,199,090 shares outstanding.
What happened to Disc Medicine, Inc.’s price movement after its last earnings report?
Disc Medicine, Inc. reported an EPS of -$1.65 in its last earnings report, missing expectations of -$1.623. Following the earnings report the stock price went down -0.074%.
Which hedge fund is a major shareholder of Disc Medicine, Inc.?
Currently, no hedge funds are holding shares in IRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Disc Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$103.14 (43.71% Upside)
$103.14 (43.71% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 246.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
42.46%
12-Months-Change
Fundamentals
Return on Equity
-36.95%
Trailing 12-Months
Asset Growth
5.77%
Trailing 12-Months
Company Description
Disc Medicine, Inc.
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
IRON Stock 12 Month Forecast
Average Price Target
$103.14
▲(43.71% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.35% Insiders
28.20% Mutual Funds
12.87% Other Institutional Investors
37.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---